Candel Therapeutics, Inc.
NASDAQ:CADLBiotechnology
+$0.05 today
- Market cap
- $417.33M
- Beta
- -0.48
- P/E (TTM)
- -9.2
- EPS (TTM)
- -$0.87
Volume 1.39M
Average 1.82M
CADL Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Candel Therapeutics, Inc.NASDAQ: CADL
Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Free cash flow growth accelerates
Q1 FY2026 free cash flow of $18.71M (cash outflow) rose 117.1% year over year, ahead of the +80.0% change in trailing-twelve-month free cash flow. Sequentially, it rose 70.5% from the prior quarter. Over 3 fiscal years it compounded at +5.9% a year.
Context
- Free cash flow grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +117.1% holds above the trailing-twelve-month pace of +80.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (38.9M) USD
- Year-over-year change
- -43.9%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (38.9M) | -43.9% |
| FY2024 | 2024-12-31 | (27.04M) | +22.1% |
| FY2023 | 2023-12-31 | (34.7M) | -6.1% |
| FY2022 | 2022-12-31 | (32.72M) | -36.0% |
| FY2021 | 2021-12-31 | (24.05M) | — |
Free Cash Flow vs competitors
How CADL compares with its peers on the latest reported figures
- Peers report in different currencies, so free cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +80.0% is the 2nd highest of 9, against a peer median of -1.9%.
- Over three fiscal years its annual growth of +5.9% compares with a peer median of +24.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $278.35M USD | -2.9% | +34.1% | 128.2% | |
| LTM Sep 2026 | $216.06M USD | -38.6% | +2.4% | 57.0% | |
| LTM Mar 2026 | $111.36M USD | -4.5% | +13.9% | — | |
| LTM Mar 2026 | $95.91M USD | -16.0% | +85.0% | — | |
| LTM Mar 2026 | $71.69M USD | -1.0% | -2.9% | 45.6% | |
| LTM Mar 2026 | $53.6M USD | +72.0% | — | 23.6% | |
| LTM Mar 2026 | $48.99M USD | +80.0% | +5.9% | — | |
| LTM Mar 2026 | $32.77M USD | +144.6% | +49.3% | — | |
GNLXGenelux Corporation | LTM Mar 2026 | $27.88M USD | +22.9% | +93.8% | 348512.5% |
NBPNovaBridge Biosciences | LTM Sep 2025 | CN¥13.15M CNY | — | -73.8% | — |
| Peer median (excluding CADL) | — | -1.9% | +24.0% | 57.0% | |
Competitors are the stored peer set for CADL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (36.12M) | (18.79M) | (37.94M) | (55.18M) | (38.18M) |
| Depreciation & Amortization | 232K | 778K | 1.28M | 990K | 845K |
| Deferred Income Tax | 11.51M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.96M | 2.31M | 3.09M | 5.31M | 3.82M |
| Change in Working Capital | (876K) | 71K | (378K) | 346K | 2.19M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 669K | (1.21M) | 45K | (185K) | 802K |
| Other Working Capital | (1.55M) | 1.28M | (378K) | 531K | 1.39M |
| Other Non-Cash Items | 76K | (15.78M) | (301K) | 21.51M | (6.98M) |
| Operating Cash Flow | (22.22M) | (31.42M) | (34.24M) | (27.02M) | (38.31M) |
| Capital Expenditures | (1.84M) | (1.3M) | (457K) | (16K) | (587K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 27K |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 177K | 0 | 0 |
| Investing Cash Flow | (1.84M) | (1.3M) | (280K) | (16K) | (560K) |
| Debt Repayment | 0 | 19.91M | 0 | (9.17M) | 36.21M |
| Common Stock Issued | 71.34M | 0 | 0 | 101.76M | 19.89M |
| Common Stock Repurchased | 0 | 0 | (121K) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 465K | 64K | 0 | 1.69M | 0 |
| Financing Cash Flow | 71.8M | 19.97M | (121K) | 94.28M | 56.1M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 47.75M | (12.74M) | (34.65M) | 67.24M | 17.23M |
| Free Cash Flow | (24.05M) | (32.72M) | (34.7M) | (27.04M) | (38.9M) |
Candel Therapeutics, Inc.
NASDAQ:CADL
Intrinsic Alpha fair value
Locked
Current Price
$5.32
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.